Dyadic to Present at Industry Events in November
30 oct. 2023 08h30 HE
|
Dyadic International, Inc.
Dyadic to Present at Industry Events in November
Dyadic to Report Third Quarter 2023 Financial Results on Wednesday, November 8, 2023
25 oct. 2023 16h30 HE
|
Dyadic International, Inc.
JUPITER, Fla., Oct. 25, 2023 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building...
Dyadic Appoints Doug Pace to Its Executive Leadership Team
09 oct. 2023 08h30 HE
|
Dyadic International, Inc.
JUPITER, Fla., Oct. 09, 2023 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building...
Dyadic’s C1 Platform Selected by the Vaccine and Immunotherapy Center (“VIC”) at Massachusetts General Hospital as Part of VIC’s $5.88 Million Award by U.S. DoD to Develop a Self-Assembling Vaccine (SAV) Platform for Rapid Production of Prophylactic Vaccines for Infectious Diseases
05 oct. 2023 08h30 HE
|
Dyadic International, Inc.
JUPITER, Fla., Oct. 05, 2023 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building...
Dyadic to Report Second Quarter 2023 Financial Results on Wednesday, August 9, 2023
26 juil. 2023 16h30 HE
|
Dyadic International, Inc.
JUPITER, Fla., July 26, 2023 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building...
Dyadic to Participate at Upcoming Events in June
01 juin 2023 08h30 HE
|
Dyadic International, Inc.
JUPITER, Fla., June 01, 2023 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial...
Dyadic Announces First Quarter 2023 Financial Results and Highlights Recent Company Progress
10 mai 2023 16h00 HE
|
Dyadic International, Inc.
New research collaboration with a Top 5 pharmaceutical company to develop C1 expressed vaccine antigen for human healthExpanded licensing agreement with Rubic One Health (“Rubic”) to develop,...
Dyadic to Report First Quarter 2023 Financial Results on Wednesday, May 10, 2023
26 avr. 2023 16h30 HE
|
Dyadic International, Inc.
JUPITER, Fla., April 26, 2023 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building...
Dyadic Announces Expanded Licensing Agreement to Develop and Commercialize Vaccines and Biologics for African Continent
12 avr. 2023 08h00 HE
|
Dyadic International, Inc.
JUPITER, Fla., April 12, 2023 (GLOBE NEWSWIRE) -- Dyadic International, Inc. ("Dyadic", "we", "us", "our", or the "Company") (NASDAQ: DYAI), a global biotechnology company focused on building...
Dyadic to Present at World Vaccine Congress Washington 2023
30 mars 2023 08h30 HE
|
Dyadic International, Inc.
JUPITER, Fla., March 30, 2023 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial...